Turnstone Biologics Corp. Common Stock Cash Flow Conversion Efficiency
Turnstone Biologics Corp. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Turnstone Biologics Corp. Common Stock (TSBX) has a cash flow conversion efficiency ratio of -0.292x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.30 Million) by net assets ($14.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Turnstone Biologics Corp. Common Stock (2021–2024)
Cash flow conversion efficiency of Turnstone Biologics Corp. Common Stock from 2021 to 2024. This chart illustrates how Turnstone Biologics Corp. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Turnstone Biologics Corp. Common Stock stock quote for real-time trading data and today's change.
Turnstone Biologics Corp. Common Stock Cash Flow Conversion Ratio Explained
Turnstone Biologics Corp. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Turnstone Biologics Corp. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Turnstone Biologics Corp. Common Stock ranked by their cash flow conversion efficiency. Also see Turnstone Biologics Corp. Common Stock (TSBX) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mercer International Inc
F:AEZ
|
0.154x |
|
Zaklady Urzadzen Kotlowych Staporkow SA
WAR:ZUK
|
0.030x |
|
Progressive Impact Corporation Bhd
KLSE:7201
|
0.084x |
|
WALKER RIVER RES CORP
F:1WV0
|
-0.019x |
|
South Ocean Holdings Ltd
JSE:SOH
|
-0.339x |
|
Walker River Resources Corp.
V:WRR
|
-0.019x |
|
Northann Corp.
NYSE MKT:NCL
|
-0.204x |
|
Miraculum SA
WAR:MIR
|
0.012x |
Annual Cash Flow Conversion Efficiency for Turnstone Biologics Corp. Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of Turnstone Biologics Corp. Common Stock from 2021 to 2024. Review Turnstone Biologics Corp. Common Stock (TSBX) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $31.47 Million | $-67.44 Million | -2.143x | -219.65% |
| 2023-12-31 | $98.67 Million | $-66.15 Million | -0.670x | -195.73% |
| 2022-12-31 | $-101.47 Million | $-71.06 Million | 0.700x | +25.63% |
| 2021-12-31 | $-81.85 Million | $-45.63 Million | 0.557x | -- |
About Turnstone Biologics Corp. Common Stock
Turnstone Biologics Corp. operates as a biotechnology company. The company was founded in 2014 and is headquartered in San Diego, California. As of August 11, 2025, Turnstone Biologics Corp. operates as a subsidiary of XOMA Royalty Corporation.